Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O14773: Variant p.Arg127Gln

Tripeptidyl-peptidase 1
Gene: TPP1
Feedback?
Variant information Variant position: help 127 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glutamine (Q) at position 127 (R127Q, p.Arg127Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CLN2; displays residual enzyme activity; effectively transported to the lysosome. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 127 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 563 The length of the canonical sequence.
Location on the sequence: help GAQKCHSVITQDFLTCWLSI R QAELLLPGAEFHHYVGGPTE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHY-------VGGPTE

                              GARNCHSVTTQDFLTCWLSVRQAELLLSGAEFHRY------

Chimpanzee                    GARKCHSVITQDFLTCWLSIRQAELLLPGAEFHHY------

Mouse                         GARNCDSVTTQDFLTCWLSVRQAELLLPGAEFHRY------

Rat                           GARDCHSVTTQDFLTCWLSVRQAELLLPGAEFHRY------

Bovine                        GARNCHSVTTQDFLTCWLSVRQAELLLSGAEFHHY------

Zebrafish                     GVMDCHTIITRDFLQCVMTVEVAEALLPGSKFHRF------

Slime mold                    DINEFTVTKSGDFIRTIVSIDKAEELLS-VRYNKM------

Baker's yeast                 F---NSKKSTLDYLCNIIDND--------------------

Fission yeast                 ENVIRPLIHYKYWPSSEVDENEEQWWRDYVKMNHAFADKIC
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Propeptide 20 – 195 Removed in mature form
Alternative sequence 1 – 243 Missing. In isoform 2.
Helix 126 – 132



Literature citations
Heterogeneity of late-infantile neuronal ceroid lipofuscinosis.
Zhong N.; Moroziewicz D.N.; Ju W.; Jurkiewicz A.; Johnston L.; Wisniewski K.E.; Brown W.T.;
Genet. Med. 2:312-318(2000)
Cited for: VARIANTS CLN2 GLN-127; VAL-284; ASN-428 AND ARG-473; Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.
Steinfeld R.; Heim P.; von Gregory H.; Meyer K.; Ullrich K.; Goebel H.H.; Kohlschutter A.;
Am. J. Med. Genet. 112:347-354(2002)
Cited for: VARIANTS CLN2 GLN-127; SER-286 AND PRO-353; Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I.
Walus M.; Kida E.; Golabek A.A.;
Hum. Mutat. 31:710-721(2010)
Cited for: VARIANT CLN2 SER-544; CHARACTERIZATION OF VARIANTS CLN2 ARG-77; GLN-127; LEU-202; CYS-206; MET-277; VAL-284; SER-286; ASN-287; LYS-343; ARG-365; HIS-422; HIS-447; LEU-475 AND SER-544;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.